Nova Measuring Instruments Ltd. — FY2019 Form 20-F
Reporting period: Fiscal year ended December 31, 2019. Although the request references 2019 Q4, this annual filing reports full-year results and does not provide a clear standalone Q4 financial summary. All amounts below are in U.S. dollars unless stated otherwise.
Business context
Nova designs and sells metrology and process-control systems for semiconductor manufacturing, including integrated and standalone optical measurement tools, X-ray materials metrology, and related software. Demand depends heavily on semiconductor manufacturers’ capital spending and technology transitions. Sales are concentrated among a small number of large customers and primarily in Asia.
Key financial metrics
| Metric | FY2019 | FY2018 |
|---|---|---|
| Revenue | $224.9 million | $251.1 million |
| Gross profit / margin | $121.8 million / 54.2% | $145.2 million / 57.8% |
| Operating income / margin | $36.4 million / 16.2% | $60.4 million / 24.1% |
| Net income | $35.2 million | $54.4 million |
| Diluted EPS | $1.23 | $1.89 |
| Operating cash flow | $41.2 million | $36.1 million |
| Cash, cash equivalents and bank deposits | $191.1 million | $177.8 million |
| Working capital | $256.0 million | $233.5 million |
| Total assets / shareholders’ equity | $400.4 million / $314.5 million | $333.4 million / $280.7 million |
Product revenue was $167.2 million, down 13.5%; service revenue was $57.7 million, essentially flat. Product and service gross margins were 59.7% and 38.0%, respectively. Nova reported no significant long-term borrowing; operating lease liabilities were $33.3 million at year-end, following adoption of ASC 842. Capital expenditures were $21.3 million, primarily for new facilities, and the company expected approximately $10 million of capital spending in 2020.
Changes versus FY2018
- Revenue declined 10.4%, following 13.1% growth in 2018. Management attributed the 2019 product-sales decline to lower wafer-fab equipment investment, affecting both optical CD and XPS products.
- Gross margin fell 3.6 percentage points, reflecting lower sales, product mix and higher costs associated with new product generations; service margin also declined, mainly due to personnel costs.
- Operating income declined 39.8% and net income declined 35.3%. Operating expenses rose slightly in dollars but increased as a share of revenue.
- Operating cash flow increased to $41.2 million, with management citing improved receivables collection. Inventories increased to $48.4 million from $41.8 million.
- Revenue geography shifted: Taiwan represented 37% of sales versus 31% in 2018, while Korea fell to 9% from 21%. The three largest customers accounted for 56% of revenue, and the five largest for 67%.
Outlook, risks and unusual items
- Nova did not provide quantified company-specific revenue or earnings guidance. Its 2020 priorities include new product development, expanding applications and markets, software and machine-learning offerings, and supporting advanced logic and memory customers. The company expected aggregate operating expenses to increase in 2020.
- Gartner forecasts cited in the filing, published December 2019 and before the COVID-19 outbreak, projected 2020 semiconductor revenue growth of 12.5%, but a 1.1% decline in wafer-fab equipment sales. These are industry estimates, not Nova guidance.
- Management identified semiconductor-industry cyclicality, technology and competitive shifts, customer and product concentration, and the ability to deliver new products on time as key risks. The filing also flags COVID-19-related travel, customer-site access and supply-chain uncertainty, as well as trade restrictions and export limits affecting Jinhua.
- Currency exposure is material: the U.S. dollar depreciated approximately 7.8% against the NIS in 2019. Nova used currency forwards and options to hedge some NIS expenses.
- Cash concentration warrants attention: substantially all cash reserves were held in banks, with approximately 40% at one institution. Nova also repurchased 276,747 shares for $7.2 million in 2019; cumulative repurchases under its $25 million program were $12.0 million through year-end.
- Inventory write-downs were $4.4 million in 2019. The auditor identified valuation of excess and obsolete inventory as a critical audit matter. Nova reported no significant ongoing legal proceedings and stated that internal controls over financial reporting were effective; the auditor gave unqualified opinions on the financial statements and controls.
- Non-cancelable purchase obligations totaled $16.4 million. Government R&D funding and Israeli tax incentives carry conditions, including restrictions on certain technology transfers and manufacturing outside Israel.
Important facts for investors to verify
- Obtain the relevant quarterly report or earnings release for standalone Q4 2019 results; this 20-F does not clearly provide them.
- Check subsequent disclosures on COVID-19 impacts, 2020 customer demand, shipments, and supply-chain conditions; the industry forecasts cited here predate the outbreak.
- Review customer concentration, regional sales trends, and the sustainability of product and service margins as sales recover or weaken.
- Assess inventory composition, reserves and future demand assumptions, including the $4.4 million annual write-down and the audit matter.
- Review lease commitments, facility utilization, planned capital spending, cash-bank concentration, and NIS exposure and hedging.
- Confirm the status and terms of Israeli R&D grants and tax benefits, including any potential repayment, approval or tax consequences.